Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Suvizumab

Copy Product Info
😃Good
Catalog No. T76991Cas No. 914257-21-9
Alias KD-247

Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.

Suvizumab

Suvizumab

Copy Product Info
😃Good
Catalog No. T76991Alias KD-247Cas No. 914257-21-9
Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$2472-4 weeks2-4 weeks
5 mg$6972-4 weeks2-4 weeks
10 mg$1,0802-4 weeks2-4 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.
Targets&IC50
HIV-1 SF2:1.0 μg/mL, HIV-1 MN:0.1 µg/mL, HIV-1 89.6:0.2 µg/mL
In vitro
In neutralization assays, Suvizumab (KD-247) demonstrates potent activity against multiple HIV-1 strains, with IC50 values of 0.1 µg/mL for HIV-1MN, 0.2 µg/mL for HIV-189.6, and 1.0 µg/mL for HIV-1SF2; however, the antibody shows significant resistance to pseudoviruses carrying the G314E mutation within the V3 loop [2][3].
In vivo
In pharmacological studies using cynomolgus macaque models infected with SHIV C2/1, intravenous administration of Suvizumab (15, 30, and 45 mg/kg) dose-dependently reduced plasma viremia and increased CD4+ T-cell counts; furthermore, repeated weekly doses (45 mg/kg) for two months significantly mitigated the loss of CD4+ T cells in lymphoid tissues and provided sterile protection against viral challenge [2][4].
SynonymsKD-247
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetHIV-1 MN/HIV-1 SF2/HIV-1 89.6
Chemical Properties
Cas No.914257-21-9
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Suvizumab | purchase Suvizumab | Suvizumab cost | order Suvizumab | Suvizumab in vivo | Suvizumab in vitro